Showing 31-40 of 58 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Antigen-specific immunotherapies based on ignored ß-cell antigen determinants. | The Regents of the University of California, Los Angeles | Daniel Kaufman | Cures | 01-October-2024 to 30-September-2027 | $573.101,00 |
| Multiplex in vivo imaging of the dynamics of immune-mediated rejection of allogenic islet grafts | The Regents of the University of California, Los Angeles | Oluwatayo Ikotun | Cures | 01-February-2024 to 31-January-2027 | $749.996,25 |
| Building the Evidence to Address Disparities in Young children with Type 1 Diabetes: BEADY-T1D | Stanford University | Ananta Addala | Improving Lives | 01-February-2025 to 31-January-2029 | $943.983,20 |
| Development of ultrarapid insulin for automated insulin dosing systems | Stanford University | Danny Hung-Chieh Chou | Improving Lives | 01-July-2026 to 30-June-2028 | $1.036.315,00 |
| Ultrafast Insulin-Pramlintide Co-formulations | Stanford University | Eric Appel | Improving Lives | 01-September-2022 to 31-December-2026 | $794.960,90 |
| Development of an injectable immunomodulatory niche technology for induction of immune tolerance to islet cell transplants | Stanford University | Eric Appel | Cures | 01-January-2025 to 31-December-2026 | $600.000,00 |
| Endothelial cells for islet replacement in diabetes | Stanford University | Martin Neukam | Cures | 01-April-2024 to 31-March-2027 | $251.600,00 |
| Optimized bone marrow conditioning and tolerance assays to advance cell-based therapies for diabetes | Stanford University | Stephan Ramos | Cures | 01-March-2026 to 28-February-2029 | $285.000,00 |
| Single-arm intervention trial of TWIIST™ AID DEKA Loop insulin pump in pregnant women with pre-existing type 1 diabetes | Stanford University | Tugce Akcan | Improving Lives | 01-March-2025 to 28-February-2027 | $180.600,00 |
| Modeling immune-islet interactions in a vascularized T1D microphysiological system platform | Regents of the University of California at Irvine | Christopher Hughes | Cures | 01-October-2026 to 30-September-2027 | $300.000,00 |